

AMENDMENT TO THE CLAIMS

Claims 102, 103, 108-111, 116 and 117 are currently amended, claims 1-101, 104-107, and 112-115 are cancelled by the current amendment.

Claims 1-101 were part of prior divisional application and were not a basis of the current continuation application, claims 118-123 were cancelled by Applicant as non-elected claims in the amendment filed March 8, 2006. New claims 124-134 are added by the present amendment. This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 102 is currently amended to properly add the word “A” as addressed in the Notice of Non-Compliant Amendment. In addition, in compliance with and as addressed by the Notice of Non-Compliant Amendment dated January 30, 2007, Applicant provides a complete listing of all claims with appropriate status identifiers and removal of underlining in new claims added. This correction will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1-101. (Canceled)

102. (Currently amended) ~~An anti-inflammatory and anti-pruritic~~ A topical skin preparation for treatment of psoriasis comprising glucosamine in an emollient base.

103. (Currently amended) The topical skin preparation of claim 102, wherein ~~the topical skin preparation is used to treat insect bites on human skin~~ a percentage in weight for glucosamine in the topical skin preparation is at least 10%.

104. (Canceled)

105. (Canceled)

106. (Canceled)

107. (Canceled)

108. (Currently amended) The topical skin preparation of claim 102, further ~~including comprising at least one extract~~ antioxidant from an herbal source.

109. (Currently amended) The topical skin preparation of claim 108, wherein the herbal source is ~~witch hazel~~ selected from the group consisting of olive leaf, Oregon grapeseed, and witch hazel.

110. (Currently amended) ~~An anti-inflammatory and anti-pruritic formulation~~ A topical skin preparation for treatment of a T-cell mediated skin disorder comprising glucosamine in an emollient base, ~~(wherein the formation may be suitable for topical application on human skin, and further wherein the formulation at least partially suppresses, local to the area of topical application, the production of at least one cytokine that stimulates the proliferation of apoptosis-resistant keratinocytes.)~~

111. (Currently amended) The ~~formulation~~ topical skin preparation of claim 110 wherein ~~the formulation is used to treat insect bites on human skin a percentage in weight~~ for glucosamine in the topical skin preparation is at least 10%.

112. (Canceled)

113. (Canceled)

114. (Canceled)

115. (Canceled)

116. (Currently amended) The ~~formulation~~ topical skin preparation of claim 110 further ~~including comprising at least one antioxidant~~ extract from an herbal source.

117. (Currently amended) The ~~formulation~~ topical skin preparation of claim 116 wherein the herbal source is ~~witch hazel~~ selected from the group consisting of olive leaf, Oregon grape seed, and witch hazel.

118. (Canceled)

119. (Canceled)

120. (Canceled)

121. (Canceled)

122. (Canceled)

123. (Canceled)

124. (New) The topical skin preparation in claim 116, wherein the at least one extract is oleuropein from olive leaf.

125. (New) The topical skin preparation in claim 116, wherein the at least one extract is berberine from Oregon grape seed.

126. (New) The topical skin preparation of claim 110, wherein the T-cell mediated skin disorder is psoriasis.

127. (New) The topical skin preparation of claim 110, wherein the T-cell mediated skin disorder is induced by an insect bite.

128. (New) The topical skin preparation of claim 110, wherein the T-cell mediated skin disorder is atopic dermatitis.

129. (New) A method for treating a T-cell mediated skin disorder, comprising the steps of:

providing a topical skin preparation in an emollient base, the topical skin preparation further comprising glucosamine and at least one extract from a herbal source; and

topically applying the topical skin preparation to an affected skin area of the skin disorder.

130. (New) The method in the claim 129, wherein the T-cell mediated skin disorder is selected from the group consisting of psoriasis, atopic dermatitis, and an allergic skin reaction from insect bites or allergens.

131. (New) The method in the claim 129, wherein the herbal source is selected from the group consisting of olive leaf, Oregon grapeseed, and witch hazel.

132. (New) The method in the claim 129, wherein the one extract is oleuropein from olive leaf.

133. (New) The method in the claim 129, wherein the one extract is berberine from Oregon grapeseed.

134. (New) The method in the claim 129, wherein a percentage in weight for glucosamine in the topical skin preparation is at least 10%.